Investors will gain two new options in the public cannabis space this week, and they’re backed by two of the biggest Canadian cannabis companies out there.

Canopy Rivers, a division of Canadian licensed producer behemoth Canopy Growth (NYSE:CGC,TSX:WEED), is expected to launch on Thursday (September 20), while Australis (CSE:AUSA), a spinoff of Aurora Cannabis (TSX:ACB), listed on Wednesday (September 19).

Canopy Rivers will trade under the ticker symbol “RIV” on the TSX Venture Exchange, while Australis is on the Canadian Securities Exchange under the ticker symbol “AUSA.”

The debut of these two stocks represents a move from leading cannabis producers to seek additional entry points in the space: investment in technologies and businesses within the cannabis market.

These venture capital companies will monitor the space and seek businesses worthy of investment. A key difference between the two will be the level of involvement from the respective producers.

Australis will seek opportunities in the US market, and Aurora has announced no involvement in the management or decisions of the company. However, the cannabis producer holds the right to purchase back an ownership stake within the next 10 years.

This type of restriction is similar to the one implemented by Aphria (TSX:APH) for Liberty Health Sciences (CSE:LHS). Both Aphria and Aurora want to retain the option to enter the US market once the laws are more favorable.

“With the completion of our over-subscribed private placement, we have the funds to start executing on these opportunities immediately and deliver growth,” Scott Dowty, CEO of Australis, said in a statement.

Selected shareholders of Aurora were given one unit of Australis for every 34 outstanding Aurora shares as of August 24. The company further explained:

Each unit consists of one common share and one share purchase warrant of Australis. Each warrant entitles the holder thereof to acquire one share at an exercise price of C$0.25 per Australis share, on or prior to 4:00 p.m. (Eastern Time) on the date that is one year after the Distribution [September 19, 2018].

Alternatively, Canopy management will be heavily involved in decision making from Canopy Rivers. The investing venture has been operating throughout 2018, and is only now launching publicly.

Canopy Rivers completed a business combination with shell company AIM2 Ventures. The company’s subordinated shares will still give a vote per share on shareholder matters.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Canopy will will retain 25 percent of the stock, and will control nearly 90 percent of voting power due to dual-class, multi-voting share structure in Canopy Rivers, according to the Financial Post.

Bruce Linton, co-CEO of Canopy and acting CEO for the new venture, explained that the company continues to see a pattern in the overall space in terms of the companies it wishes to invest in or that are seeking investment from Canopy:

“There was this theme that kept coming up in the cannabis space — companies that either wanted our money and help, or that we wanted a small percentage of. And they were all somewhere along the mistake-making spectrum, but some of them had really good ideas, so we thought ‘OK, how about we have a dedicated company that really tries to figure out what might work, what might not work, and become early minority investors’.”

Linton also compared the public trajectory of Canopy Rivers to an exchange-traded fund (ETF). However, he stopped short of saying the company is intending to outperform ETFs.

As part of its most recent quarterly release, Canopy said that Canopy Rivers holds a joint venture for the creation of a new company called PharmHouse, which will seek to become a cannabis licensed producer in Ontario.

“PharmHouse has also agreed to provide Canopy Rivers with a right of first offer of up to 50 [percent] to the cannabis produced by PharmHouse,” company documents state.

Investor takeaway

These new ventures open the door for investors to support investments in the cannabis space as leading companies seek to fill in the gaps with emerging businesses.

During Australis’ first day of trading, the company’s share price soared to a high price point of C$14.48. At market close the stock finished the day valued at C$2.93 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less